Skip to content

The Randomized Controlled Clinical Trial of Autologous Platelet-Rich Plasma in Cartilage Defect

The Randomized Controlled Clinical Trial of Autologous Platelet-Rich Plasma in Cartilage Defect

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026365
Enrollment
Unknown
Registered
2019-10-03
Start date
2019-10-08
Completion date
Unknown
Last updated
2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee articular cartilage injury

Interventions

LR-PRP group:LR-PRP
Control group:Saline
LP-PRP group:LP-PRP???

Sponsors

Shanghai Changzheng Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Between the ages of 18 and 75; 2. MRI clearly indicated articular cartilage injury, Kellgren-Lawrence standard knee grade for OA was not more than level-3; 3. Obvious knee pain or discomfort symptoms and lasted for more than 3 months; 4. Wiilling to participate in the study and signed the informed consent; 5. Diagnosed articular cartilage injury has by arthroscopy, and no targeted treatment had been made.

Exclusion criteria

Exclusion criteria: 1. Other surgical procedures had been performed to treat articular cartilage; 2. A history of intra-articular injection or a history of peri-articular invasive treatments and procedures within three months; 3. Symptoms and imaging findings were localised in patellofemoral joint; 4. Patients with malignant neoplasms; 5. Active infection in other parts of the body; 6. Pregnant or lactating women or women preparing for pregnancy; 7. Cartilage lesions caused by infectious or gouty arthritis; 8. Autoimmune diseases such as rheumatoid arthritis and ankylosing spondylitis; 9. The patient had diabetes with FBG over 8mmol/ L and had poor control; 10. Patients who are generally in poor condition and cannot tolerate surgery; 11. Severe diseases such as cerebral hemorrhage, severe pneumonia and multiple organ dysfunction; 12. Charcot joint; 13. Find something may increase the patient's risk or influence the results of the experiment during the research; 14. Other reasons not fit for this study.

Design outcomes

Primary

MeasureTime frame
Knee X ray and K-L rating;Knee MRI and WORMS Score;Knee function score (VAS score, WOMAC score);

Secondary

MeasureTime frame
Blood RT, ESR, CRP;Hepatic and renal function;

Countries

China

Contacts

Public ContactQirong Qian

Shanghai Changzheng Hospital

qianqr@163.com+86 13818940205

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026